These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 7711008)
1. Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats. Golda V; Cvak L Physiol Res; 1994; 43(5):299-305. PubMed ID: 7711008 [TBL] [Abstract][Full Text] [Related]
2. Ambivalent effect of long lasting terguride treatment on genetically based glycide and lipid metabolism abnormalities in SHR/N-cp Koletsky rats. Golda V Acta Medica (Hradec Kralove); 1998; 41(2):81-5. PubMed ID: 9729641 [TBL] [Abstract][Full Text] [Related]
3. Effect of long lasting terguride treatment on mutual relationship between glycide and lipid parameters in SHR/N-cp Koletsky rats. Golda V; Hilgertová J Acta Medica (Hradec Kralove); 1998; 41(1):13-7. PubMed ID: 9588067 [TBL] [Abstract][Full Text] [Related]
4. Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats. Golda V; Hilgertová J Physiol Res; 1997; 46(6):439-42. PubMed ID: 9730050 [TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia in obese as well as in lean females of Koletsky rats: effect of long lasting terguride treatment. Golda V; Jurcovicová J Acta Medica (Hradec Kralove); 1998; 41(4):159-62. PubMed ID: 9951046 [TBL] [Abstract][Full Text] [Related]
6. Multiple regression analysis of parameters of lipid and glycide metabolism in obese and lean genetically hypertensive Koletsky rats under long lasting terguride treatment. Golda V; Hilgertová J Acta Medica (Hradec Kralove); 1996; 39(4):141-7. PubMed ID: 9270120 [TBL] [Abstract][Full Text] [Related]
7. Development of lipid and glycide abnormalities in genetically hypertensive obese Koletsky rats and in their lean siblings. Golda V; Hilgertová J Acta Medica (Hradec Kralove); 1998; 41(4):163-6. PubMed ID: 9951047 [TBL] [Abstract][Full Text] [Related]
8. Effects of terguride treatment on glucose abnormalities induced by ischemic brain damage in SHR/N-cp lean Koletsky strain and in rats of Wistar strain. Kudlackova Z; Golda V Bratisl Lek Listy; 2004; 105(10-11):353-8. PubMed ID: 15658573 [TBL] [Abstract][Full Text] [Related]
9. Glucose intolerance induced by oligemic brain hypoxia: the effect of terguride. Golda V; Hilgertová J Acta Medica (Hradec Kralove); 1997; 40(3):57-60. PubMed ID: 9465428 [TBL] [Abstract][Full Text] [Related]
10. Muscle GLUT-4 and insulin binding to erythrocytes and to adipose, liver and muscle tissue in genetically hypertensive obese rats and in their lean siblings: effect of long lasting terguride treatment. Golda V; Hilgertová J; Zórad S Acta Medica (Hradec Kralove); 1998; 41(3):125-30. PubMed ID: 9919714 [TBL] [Abstract][Full Text] [Related]
11. Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study. Mikulášková B; Holubová M; Pražienková V; Zemenová J; Hrubá L; Haluzík M; Železná B; Kuneš J; Maletínská L Nutr Diabetes; 2018 Jan; 8(1):5. PubMed ID: 29339795 [TBL] [Abstract][Full Text] [Related]
12. Terguride attenuates prolactin levels and ameliorates insulin sensitivity and insulin binding in obese spontaneously hypertensive rats. Golda V; Ficková M; Pinterova L; Jurcovicová J; Macho L; Zórad S Physiol Res; 2001; 50(2):175-82. PubMed ID: 11522045 [TBL] [Abstract][Full Text] [Related]
13. Effect of dehydroepiandrosterone on lipemia, glucose tolerance, insulinemia, insulin binding to erythrocytes in SHR/N-cp lean rats of Koletsky type. Golda V; Hilgertová J Acta Medica (Hradec Kralove); 1997; 40(2):31-5. PubMed ID: 9389208 [TBL] [Abstract][Full Text] [Related]
14. Terguride treatment attenuated prolactin release and enhanced insulin receptor affinity and GLUT 4 content in obese spontaneously hypertensive female, but not male rats. Zorad S; Golda V; Fickova M; Macho L; Pinterova L; Jurcovicova J Ann N Y Acad Sci; 2002 Jun; 967():490-9. PubMed ID: 12079879 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764 [TBL] [Abstract][Full Text] [Related]
16. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453 [TBL] [Abstract][Full Text] [Related]
17. Animal model of anxiety: the effect of chronic bromocriptine treatment in the genetically hypertensive rats of Koletsky type and in the normotensive rats of Wistar strain. Golda V; Petr R Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1990; 33(2):153-63. PubMed ID: 2098904 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894 [TBL] [Abstract][Full Text] [Related]